Literature DB >> 888883

Trabeculectomy and postoperative ocular hypertension in secondary angle-closure glaucoma.

G L Portney.   

Abstract

I performed trabeculectomies to reduce the introacular pressure to 20 mm Hg or lower, in 56 eyes with medically uncontrollable primary open-angle glaucoma or secondary angle-closure glaucoma. In the former group, I achieved success in 85% of cases, 65% without further antiglaucomatous therapy. In the latter group, 59% obtained a successful result, 41% without additional treatment. The readings of applanation tonometry on the first postsurgical day were compared to those obtained after one year. Although approximately 50% of eyes in both glaucoma categories had an initially elevated pressure after trabeculectomy, it decreased steadily in most of those with primary open-angle glaucoma. In the secondary angle closure glaucoma population, this immediate postoperative ocular hypertension was significantly correlated with eventual failure of the operation.

Entities:  

Mesh:

Year:  1977        PMID: 888883     DOI: 10.1016/0002-9394(77)90845-5

Source DB:  PubMed          Journal:  Am J Ophthalmol        ISSN: 0002-9394            Impact factor:   5.258


  5 in total

1.  Autologous hair implantation for drainage in rabbit eyes.

Authors:  G Strasser; R Haddad
Journal:  Doc Ophthalmol       Date:  1986       Impact factor: 2.379

2.  Transient ocular hypertension following trabeculectomy.

Authors:  M Prialnic; H Savir
Journal:  Br J Ophthalmol       Date:  1979-04       Impact factor: 4.638

3.  A comparison between peripheral iridectomy with thermal sclerostomy and trabeculectomy: a controlled study.

Authors:  G L Spaeth; E Poryzees
Journal:  Br J Ophthalmol       Date:  1981-11       Impact factor: 4.638

4.  Trabeculectomy: a retrospective long-term follow-up of 444 cases.

Authors:  K B Mills
Journal:  Br J Ophthalmol       Date:  1981-11       Impact factor: 4.638

5.  Raised intraocular pressure with topical steroids after trabeculectomy.

Authors:  R Thomas; J L Jay
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1988       Impact factor: 3.117

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.